One Alzheimer’s Drug Fails. Does That Spell Trouble for Its Rival?
In Simple Terms An experimental Alzheimer’s drug did not slow patients’ decline in thinking or everyday abilities, and the news sent shares in a rival company tumbling. Both companies are working on treatments aimed at…



































































































